Ablynx completes funding, raises €50 million
This article was originally published in Scrip
Executive Summary
Belgian antibody firm Ablynx has completed its secondary public offering, raising €50 million through the sale of just under 6.7 million new shares at €7.50 each. An over-allotment option of up to 400,000 shares worth €3 million in total will be covered by lending shareholders selling existing shares. The company said that the base offering at the final offer price was subscribed by about 1.1 times. The transaction leaves Ablynx with a market capitalisation of around €327 million based on the final offer price. The new shares are expected to begin trading on Euronext Brussels on March 18th. Ablynx announced its offering last week, when it set the offer price range at €7.20-7.75 (scripnews.com, March 8th, 2010).
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.